BNGO - Bionano presents data for Saphyr as a first line test in genetic disease and cancer

At the Festival of Genomics & Biodata, Dr. Alka Chaubey Chief Medical Officer of Bionano Genomics (BNGO) has presented evidence supporting the use of Optical Genome Mapping (“OGM”) with Saphyr as a first-line test in genetic disease and cancer.The company’s Saphyr system is a research-use-only platform to streamline the study of changes in chromosomes, known as cytogenetics.As a first-line test, OGM would be the first test for diagnosis of disease, the prognosis, and the patient management, the company said in a statement.After a 470% run in the trading week before the new year day, Bionano stock ‘could stall or even fall in the short term,’ forecasted Seeking Alpha contributor, John Alford in a bearish thesis on the company.

For further details see:

Bionano presents data for Saphyr as a first line test in genetic disease and cancer